Acino Holding AG : Acino welcomes German court ruling on rivastigmine

NEWS RELEASE - PRESSEMITTEILUNG

Acino welcomes German court ruling on rivastigmine Aesch, September 12, 2013, 18.30 hrs - Acino is pleased to announce a major breakthrough in the ongoing German intellectual property litigation proceedings regarding its generic rivastigmine patch. Already on August 21, 2013, Novartis and LTS (Lohmann Therapie-Systeme) admitted at the Mannheim district court that they did not have any infringement claims based on the German part of patent EP 1 047 409 B1 against

Acino's product. Today, the Dusseldorf district court further smoothed the way to a pan- European product launch by dismissing the originators' request for preliminary injunction in respect of the German utility model DE 20 2006 021 172 U1. It remains to be seen whether the originator will appeal the Dusseldorf judgment. But so far, Novartis and/or LTS have not been able to demonstrate infringement of any valid rivastigmine patent or utility model.

Acino's once-daily rivastigmine patch, which is indicated for the symptomatic treatment of mild to moderate forms of Alzheimer dementia, has received EU approval and was launched in Germany in April 2013 by betapharm as one of the first generic alternatives

to the branded product.

Acino - Delivering Health

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzerland", Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group, headquartered in Aesch BL, has 788 employees and generated revenues of EUR 143 million in the first half-year 2013.

Contact Calendar

Robert Schmid
Media & Investor Relations Phone [phone] [e-mail]
www.acino-pharma.com

6.3.2014 Annual Report 2013
6.3.2014 Media and analyst conferences
10.4.2014 General Meeting of Shareholders

Acino Holding AG

Dornacherstrasse 114

CH-4147 Aesch

Phone [phone]

Fax [phone] www.acino-pharma.com